Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
6.–10. rezultāts no 100.
534. lappuse
... drying , pH , ampicillin content , concordance , crystallinity , and identity . ( b ) The batch for potency and loss on drying . ( ii ) Samples required : ( a ) The ampicillin used in making the batch : 10 packages , each containing ...
... drying , pH , ampicillin content , concordance , crystallinity , and identity . ( b ) The batch for potency and loss on drying . ( ii ) Samples required : ( a ) The ampicillin used in making the batch : 10 packages , each containing ...
537. lappuse
... drying , pH , ampicillin content , con- cordance , crystallinity , and identity . ( b ) The batch for potency and loss on drying . ( ii ) Samples required : ( a ) The ampicillin trihydrate used in making the batch : 10 packages , each ...
... drying , pH , ampicillin content , con- cordance , crystallinity , and identity . ( b ) The batch for potency and loss on drying . ( ii ) Samples required : ( a ) The ampicillin trihydrate used in making the batch : 10 packages , each ...
540. lappuse
... drying , pH , ampicillin content , con- cordance , crystallinity , and identity . ( b ) The probenecid used in making the batch for all U.S.P. specifications . ( c ) The batch for ampicillin content , probenecid content , and loss on drying ...
... drying , pH , ampicillin content , con- cordance , crystallinity , and identity . ( b ) The probenecid used in making the batch for all U.S.P. specifications . ( c ) The batch for ampicillin content , probenecid content , and loss on drying ...
557. lappuse
... drying , pH , crystallinity , penicillin V content . ( b ) The batch for potency and loss on drying . ( ii ) Samples required : ( a ) The penicillin V potassium used in making the batch : 10 packages , each containing approximately 300 ...
... drying , pH , crystallinity , penicillin V content . ( b ) The batch for potency and loss on drying . ( ii ) Samples required : ( a ) The penicillin V potassium used in making the batch : 10 packages , each containing approximately 300 ...
558. lappuse
... drying . Proceed as directed in § 436.200 ( b ) of this chapter . [ 42 FR 59864 , Nov. 22 , 1977 , as amended at 50 ... drying , pH , penicillin V content and crystallinity . ( b ) The batch for potency , loss on drying , and ...
... drying . Proceed as directed in § 436.200 ( b ) of this chapter . [ 42 FR 59864 , Nov. 22 , 1977 , as amended at 50 ... drying , pH , penicillin V content and crystallinity . ( b ) The batch for potency , loss on drying , and ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning